User:Lisachandler/Enter your new article name here

This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft.

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs
This page was last edited by Timrollpickering (talk | contribs) 5 years ago. (Update timer)

Finished writing a draft article? Are you ready to request an experienced editor review it for possible inclusion in Wikipedia? Submit your draft for review!

Toca 511 & Toca FC

Toca 511, the key novel component of Tocagen's ^[1] first Product Candidate (Toca 511 & Toca FC) ^[2], was developed using Controlled Active Gene Transfer (CAGT) technology ^[3]. The CAGT platform is a Retroviral Replicating Vector (RRV) that carries the complete complement of viral genes (gag, pol, env) which allow viral replication and subsequent delivery of a therapeutic gene throughout a tumor^[4].

Toca 511 is intended to be used in combination with Toca FC. Toca FC is a novel extended-release tablet containing 5-FC (flucytosine).

Toca 511 & Toca FC is being investigated in a Phase I/II clinical trial for the treatment of recurrent high grade glioma (HGG) brain cancer, including glioblastoma multiforme (GBM)^[5].

References

External links

http://clinicaltrials.gov/ct2/show/NCT01156584?term=Tocagen&rank=1

[1] ttp://www.tocagen.com/site/c.quIYL6MOJrE/b.3789961/k.8FC2/Tocagen_Inc.htm

[2] ttp://www.tocagen.com/site/c.quIYL6MOJrE/b.3789961/k.8FC2/Tocagen_Inc.htm

[3] ttp://www.tocagen.com/site/c.quIYL6MOJrE/b.3791445/k.DFD0/Products.htm

[4] ttp://www.tocagen.com/site/c.quIYL6MOJrE/b.3791437/k.2AB0/Technology.htm

[5] ttp://www.nature.com/mt/journal/v12/n5/full/mt20051365a.html

[1]

[2]

[3]

[4]

[5]